Difference between revisions of "Template:Chemotherapeutic agents"
Jump to navigation
Jump to search
imported>Anypodetos |
imported>Anypodetos m (Simplify markup, replaced: • → • (46), <BR> → <br /> (7) using AWB) |
||
| Line 5: | Line 5: | ||
| groupstyle = background-color: #E5BFE5 | | groupstyle = background-color: #E5BFE5 | ||
| − | | group1 = [[Spindle poison|SP]]s/[[mitotic inhibitor|MI]]s< | + | | group1 = [[Spindle poison|SP]]s/[[mitotic inhibitor|MI]]s<br />([[M phase]]) |
| list1 = {{Navbox subgroup | | list1 = {{Navbox subgroup | ||
| groupstyle = background-color: #E5BFE5 | | groupstyle = background-color: #E5BFE5 | ||
| Line 13: | Line 13: | ||
| group2 = Block microtubule disassembly | | group2 = Block microtubule disassembly | ||
| − | | list2 = ''[[Taxane]]s'' ([[Cabazitaxel]], [[Docetaxel]], [[Larotaxel]], [[Ortataxel]], [[Paclitaxel]], [[Tesetaxel]])& | + | | list2 = ''[[Taxane]]s'' ([[Cabazitaxel]], [[Docetaxel]], [[Larotaxel]], [[Ortataxel]], [[Paclitaxel]], [[Tesetaxel]]) • ''[[Epothilone]]s'' ([[Ixabepilone]]) |
}} | }} | ||
| − | | group2 = [[DNA replication]]< | + | | group2 = [[DNA replication]]<br />inhibitor |
| list2 = {{Navbox subgroup | | list2 = {{Navbox subgroup | ||
| groupstyle = background-color: #E5BFE5 | | groupstyle = background-color: #E5BFE5 | ||
| − | | group1 = DNA precursors/< | + | | group1 = DNA precursors/<br />[[antimetabolite]]s<br />([[S phase]]) |
| list1 = {{Navbox subgroup | | list1 = {{Navbox subgroup | ||
| groupstyle = background-color: #E5BFE5 | | groupstyle = background-color: #E5BFE5 | ||
| Line 27: | Line 27: | ||
| group1 = [[Antifolate|Folic acid]] | | group1 = [[Antifolate|Folic acid]] | ||
| − | | list1 = ''[[dihydrofolate reductase inhibitor]]'' ([[Aminopterin]], [[Methotrexate]], [[Pemetrexed]], [[Pralatrexate]])& | + | | list1 = ''[[dihydrofolate reductase inhibitor]]'' ([[Aminopterin]], [[Methotrexate]], [[Pemetrexed]], [[Pralatrexate]]) • ''[[thymidylate synthase inhibitor]]'' ([[Raltitrexed]], [[Pemetrexed]]) |
| group2 = [[Purine analogue|Purine]] | | group2 = [[Purine analogue|Purine]] | ||
| list2 = ''[[adenosine deaminase inhibitor]]'' ([[Pentostatin]]) | | list2 = ''[[adenosine deaminase inhibitor]]'' ([[Pentostatin]]) | ||
| − | ''[[halogenated]]/[[ribonucleotide reductase inhibitor]]s'' ([[Cladribine]], [[Clofarabine]], [[Fludarabine]])< | + | ''[[halogenated]]/[[ribonucleotide reductase inhibitor]]s'' ([[Cladribine]], [[Clofarabine]], [[Fludarabine]])<br /> |
''[[thiopurine]]'' ([[Tioguanine|Thioguanine]], [[Mercaptopurine]]) | ''[[thiopurine]]'' ([[Tioguanine|Thioguanine]], [[Mercaptopurine]]) | ||
| Line 50: | Line 50: | ||
}} | }} | ||
| − | | group2 = [[Topoisomerase inhibitor]]s< | + | | group2 = [[Topoisomerase inhibitor]]s<br />([[S phase]]) |
| list2 = {{Navbox subgroup | | list2 = {{Navbox subgroup | ||
| groupstyle = background-color: #E5BFE5 | | groupstyle = background-color: #E5BFE5 | ||
| Line 61: | Line 61: | ||
| group3 = [[Topoisomerase_II#Inhibition|II]]+[[Intercalation (chemistry)|Intercalation]] | | group3 = [[Topoisomerase_II#Inhibition|II]]+[[Intercalation (chemistry)|Intercalation]] | ||
| − | | list3 = ''[[Anthracycline]]s'' ([[Aclarubicin]], [[Daunorubicin]], [[Doxorubicin]], [[Epirubicin]], [[Idarubicin]], [[Amrubicin]], [[Pirarubicin]], [[Valrubicin]], [[Zorubicin]])& | + | | list3 = ''[[Anthracycline]]s'' ([[Aclarubicin]], [[Daunorubicin]], [[Doxorubicin]], [[Epirubicin]], [[Idarubicin]], [[Amrubicin]], [[Pirarubicin]], [[Valrubicin]], [[Zorubicin]]) • ''[[Anthracenedione]]s'' ([[Mitoxantrone]], [[Pixantrone]]) |
}} | }} | ||
| − | | group3 = [[Crosslinking of DNA]]< | + | | group3 = [[Crosslinking of DNA]]<br />([[cell-cycle nonspecific antineoplastic agents|CCNS]]) |
| list3 = {{Navbox subgroup | | list3 = {{Navbox subgroup | ||
| groupstyle = background-color: #E5BFE5 | | groupstyle = background-color: #E5BFE5 | ||
| group1 = [[Alkylating antineoplastic agent|Alkylating]] | | group1 = [[Alkylating antineoplastic agent|Alkylating]] | ||
| − | | list1 = ''[[Nitrogen mustard]]s:'' [[Mechlorethamine]]& | + | | list1 = ''[[Nitrogen mustard]]s:'' [[Mechlorethamine]] • [[Cyclophosphamide]] ([[Ifosfamide]], [[Trofosfamide]]) • [[Chlorambucil]] ([[Melphalan]], [[Prednimustine]]) • [[Bendamustine]] • [[Uramustine]] • [[Estramustine]] |
| − | ''[[Nitrosourea]]s:'' [[Carmustine]]& | + | ''[[Nitrosourea]]s:'' [[Carmustine]] • [[Lomustine]] ([[Semustine]]) • [[Fotemustine]] • [[Nimustine]] • [[Ranimustine]] • [[Streptozotocin|Streptozocin]] |
''[[Alkyl sulfonate]]s:'' [[Busulfan]] ([[Mannosulfan]], [[Treosulfan]]) | ''[[Alkyl sulfonate]]s:'' [[Busulfan]] ([[Mannosulfan]], [[Treosulfan]]) | ||
| − | ''[[Aziridine]]s:'' [[Carboquone]]& | + | ''[[Aziridine]]s:'' [[Carboquone]] • [[ThioTEPA]] • [[Triaziquone]] • [[Triethylenemelamine]] |
| group2 = [[Alkylating_antineoplastic_agent#Alkylating-like|Alkylating-like]] | | group2 = [[Alkylating_antineoplastic_agent#Alkylating-like|Alkylating-like]] | ||
| Line 83: | Line 83: | ||
|group3 = [[Alkylating_antineoplastic_agent#Nonclassical|Nonclassical]] | |group3 = [[Alkylating_antineoplastic_agent#Nonclassical|Nonclassical]] | ||
| − | |list3 = ''[[Hydrazine]]s'' ([[Procarbazine]])& | + | |list3 = ''[[Hydrazine]]s'' ([[Procarbazine]]) • ''[[Triazene]]s'' ([[Dacarbazine]], [[Temozolomide]]) • [[Altretamine]] • [[Mitobronitol]] |
|group4 = [[Intercalation (chemistry)|Intercalation]] | |group4 = [[Intercalation (chemistry)|Intercalation]] | ||
| Line 94: | Line 94: | ||
| group4 = [[Photosensitizer]]s/[[Photodynamic therapy|PDT]] | | group4 = [[Photosensitizer]]s/[[Photodynamic therapy|PDT]] | ||
| − | | list4 = [[D-Aminolevulinic acid|Aminolevulinic acid]]/[[Methyl aminolevulinate]]& | + | | list4 = [[D-Aminolevulinic acid|Aminolevulinic acid]]/[[Methyl aminolevulinate]] • [[Efaproxiral]] • ''[[Porphyrin|Porphyrin derivatives]]'' ([[Porfimer sodium]], [[Talaporfin]], [[Temoporfin]], [[Verteporfin]]) |
| group5 = Other | | group5 = Other | ||
| Line 101: | Line 101: | ||
| group1 = [[Enzyme inhibitor]]s | | group1 = [[Enzyme inhibitor]]s | ||
| − | | list1 = ''[[Farnesyltransferase inhibitor|FI]]'' ([[Tipifarnib]]) & | + | | list1 = ''[[Farnesyltransferase inhibitor|FI]]'' ([[Tipifarnib]]) • ''[[cyclin-dependent kinase|CDK]] [[Protein kinase inhibitor|inhibitor]]s'' ([[Alvocidib]], [[Seliciclib]]) • ''[[Proteasome inhibitor|PrI]]'' ([[Bortezomib]]) • ''[[Phosphodiesterase inhibitor|PhI]]'' ([[Anagrelide]]) • ''[[IMP dehydrogenase|IMPDI]]'' ([[Tiazofurine]]) • ''[[Lipoxygenase inhibitor|LI]]'' ([[Masoprocol]]) • ''[[PARP inhibitor]]'' ([[Olaparib]]) • ''[[Histone deacetylase inhibitor|HDAC]]'' ([[Vorinostat]], [[Romidepsin]]) |
| group2 = [[Receptor antagonist]]s | | group2 = [[Receptor antagonist]]s | ||
| − | | list2 = ''[[Endothelin receptor antagonist|ERA]]'' ([[Atrasentan]])& | + | | list2 = ''[[Endothelin receptor antagonist|ERA]]'' ([[Atrasentan]]) • ''[[retinoid X receptor]]'' ([[Bexarotene]]) • ''[[sex steroid]]'' ([[Testolactone]]) |
|group3 = Other/ungrouped | |group3 = Other/ungrouped | ||
| − | |list3 = [[Amsacrine]]& | + | |list3 = [[Amsacrine]] • [[Trabectedin]] • ''[[retinoid]]s'' ([[Alitretinoin]], [[Tretinoin]]) • [[Arsenic trioxide]] • ''[[Asparagine|asparagine depleter]]s'' ([[Asparaginase]]/[[Pegaspargase]]) • [[Celecoxib]] • [[Demecolcine]] • [[Elesclomol]] • [[Elsamitrucin]] • [[Etoglucid]] • [[Lonidamine]] • [[Lucanthone]] • [[Mitoguazone]] • [[Mitotane]] • [[Oblimersen]] • [[Omacetaxine mepesuccinate]] • ''[[mTOR inhibitor]]s'' ([[Everolimus]], [[Temsirolimus]]) |
}} | }} | ||